VIDEO: Investigating PD-1 inhibitor for treatment of lung cancer

ByRoy Herbst, MD, PhD

In this video, Roy S. Herbst, MD, PhD, associate cancer center director for translational research at Yale Cancer Center, explained findings from the phase 3 trial, EMPOWER-Lung 1.

The researchers investigated the activity of cemiplimab (Libtayo; Sanofi, Regeneron), a PD-1 inhibitor already approved for the treatment of subcutaneous skin cancer, against advance non-small cell lung cancer.

“It’s still early; we have to wait a bit longer,” Herbst, who also serves as ensign professor of medicine and professor of pharmacology, and chief of medical oncology at Yale Cancer Center and Smilow Cancer Hospital, said. “But I think these data show there’s another ... player in the field.”

References:

Sezer A, et al. Abstract LBA52. Presented at: European Society for Medical Oncology Virtual Congress 2020; Sept. 19-21, 2020.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Herbst reports receiving research support from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck and Company, and serving as a board member for Junshi Pharmaceuticals and as a consultant for AbbVie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol‐Myers Squibb, Cybrexa, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Mirati Therapeutics, Nektar, Neon Therapeutics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen and WindMIL Therapeutics.

Take Homes in Lung Cancer

Read more

VIDEO: Investigating PD-1 inhibitor for treatment of lung cancer

References:

Related Content